Breathe™ easy: Cambridge Consultants technology adds intelligence and automation to aspiration procedures


Firm develops first ever digital device for collapsed lung aspiration, enhancing value of operation for doctors and hospitals and reducing the invasiveness of the procedure Cambridge Consultants, a leading technology product design and development firm, today announced a novel process to automate the procedure of aspiration for Primary Spontaneous Pneumothorax (PSP), also known as a …




Continue reading

Putting the patient first: students work with elderly to define the next stage of the connected health revolution


Recent collaboration with Tufts University students and Cambridge Consultants offers glimpse into how different generations interact with emerging health technologies Cambridge Consultants, a leading technology product design and development firm, today shared recommendations on how to increase adoption of new connected health technologies that will help to improve wellness among the nation’s growing elderly population. …




Continue reading

Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma


Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase (CDK) inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).






Continue reading